Product nameAnti-NAPE-PLD antibody
See all NAPE-PLD primary antibodies
DescriptionRabbit polyclonal to NAPE-PLD
Tested applicationsSuitable for: ICC/IF, IHC-P, WBmore details
Species reactivityReacts with: Human
- IHC-P: Human kidney tissue. ICC/IF: A431 cells. WB: Human liver tissue lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 40% Glycerol, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab246951 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 - 4 µg/ml.
Fixation/Permeabilization: PFA/Triton X-100
|IHC-P||1/50 - 1/200. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|WB||Use a concentration of 0.4 µg/ml.|
FunctionHydrolyzes N-acyl-phosphatidylethanolamines (NAPEs) to produce N-acylethanolamines (NAEs) and phosphatidic acid. Responsible for the generation of anandamide (N-arachidonoylethanolamine), the ligand of cannabinoid and vanilloid receptors.
Sequence similaritiesBelongs to the NAPE-PLD family.
- Information by UniProt
- C7orf18 antibody
- DKFZp781D1098 antibody
- FMP30 antibody
FA fixed, Triton X-100 permeabilized A431 (Human epidermoid carcinoma cell line) cells labeling NAPE-PLD using ab246951 at 4 µg/ml (green) in ICC/IF.
Paraffin-embedded human kidney tissue stained for NAPE-PLD using ab246951 at 1/50 dilution in immunohistochemical analysis.
All lanes : Anti-NAPE-PLD antibody (ab246951) at 0.4 µg/ml
Lane 1 : RT4 (Human urinary bladder cancer cell line) cell lysate
Lane 2 : U-251 MG (Human brain glioma cell line) cell lysate
Lane 3 : Human plasma (IgG/HSA depleted)
Lane 4 : Human liver tissue lysate
ab246951 has not yet been referenced specifically in any publications.